Previous Article | Next Article ![]()
Journal of Virology, February 1999, p. 907-919, Vol. 73, No. 2
INSERM CJF 94/03,
Received 30 July 1998/Accepted 20 October 1998
In vivo targeting of therapeutic genes to specific tissues has
become a major issue in gene therapy, in particular when recombinant adenovirus vectors are used. Restriction of the viral tropism to
selected cell types requires the abrogation of the interaction between
the viral fiber and its natural cellular receptors and the introduction
of a new binding specificity into the virion. In this context,
fiberless adenoviruses are attractive vectors, since they may be used
as substrates for the insertion of a new ligand in other capsid
proteins. In this study, we confirm by using cloned full-length
adenovirus genomes with the fiber gene deleted that efficient virus
particle formation can occur in the absence of fiber. As expected, the
infectivity of such fiberless viruses was severely reduced, but it
could be only partially restored when the viruses were produced in
cells stably providing the fiber in trans. Although
incorporation of penton base into the fiberless particles was normal
and binding of the particles to the cellular integrins was functional,
several pieces of experimental evidence suggest that later steps in the
cell entry process are impaired in correlation with an incorrect
maturation of several structural proteins of the fiberless particles.
These observations support the hypothesis that the fiber protein may
have additional biological functions besides its role in cell binding.
Together with the fiber complementation cells, such fiberless vectors
constitute unique tools to investigate the role of the fiber in virus
assembly, maturation, and cell entry and to explore the possibility of
deriving gene transfer vectors with novel target specificities.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Fiberless Recombinant Adenoviruses: Virus
Maturation and Infectivity in the Absence of Fiber
*
Corresponding author. Mailing address: Transgène
S.A., 11 rue de Molsheim, 67000 Strasbourg, France. Phone: (33) 388 27 91 68. Fax: (33) 388 27 91 11. E-mail: mehtali{at}transgene.fr.
Journal of Virology, February 1999, p. 907-919, Vol. 73, No. 2
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|